Pacligen (Paclitaxel)

Pacligen is an antineoplastic medication that targets solid‑tumor malignancies. It is employed in several established oncology protocols:

• Breast cancer: Improves the overall response to chemotherapy regimens.
• Ovarian cancer: Used as part of first‑line combination therapy.
• Non‑small cell lung cancer: Contributes to disease control when combined with platinum agents.
• Gastric cancer: Added to multimodal regimens to enhance tumor shrinkage.
• Kaposi sarcoma: Provides clinical benefit in advanced disease.
• Pancreatic cancer: Integrated into combination regimens for advanced disease.

• Paclitaxel binds to the β‑tubulin subunit of microtubules, promoting polymerisation and stabilising the microtubule network. This prevents normal depolymerisation required for mitotic spindle disassembly, thereby arresting cells in the G2/M phase of the cell cycle and triggering apoptotic pathways in rapidly dividing cancer cells.

Pacligen may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: Reduced white‑blood‑cell count increasing infection risk.
• Alopecia: Hair loss affecting scalp and body hair.
• Peripheral neuropathy: Tingling or numbness in extremities.
• Nausea and vomiting: Gastro‑intestinal upset common during infusion.
• Fatigue: Generalised tiredness during treatment cycles.
• Myalgia: Muscle aches and discomfort.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: Anaphylaxis‑like symptoms requiring immediate medical attention.
• Cardiotoxicity: Arrhythmias or reduced cardiac function in susceptible patients.
• Severe neutropenic fever: Life‑threatening infection with fever.
• Pulmonary toxicity: Interstitial pneumonitis or acute respiratory distress.
• Hepatotoxicity: Elevated liver enzymes indicating liver injury.
• Thromboembolic events: Blood clots forming in veins or arteries.

When using Pacligen, clinicians should observe several safety measures:

• Baseline assessment: Perform complete blood count and liver function tests before initiation.
• Monitoring: Conduct regular hematologic and hepatic monitoring throughout therapy.
• Premedication: Administer corticosteroids and antihistamines to reduce infusion‑related reactions.
• Dose adjustments: Modify dose in patients with hepatic impairment or severe neutropenia.
• Contraindications: Avoid use in patients with known hypersensitivity to paclitaxel or its excipients.
• Store at ambient temperature: Keep below 25°C, protect from moisture and light, and retain in original packaging.

Pacligen can interact with several concomitant medicines, influencing efficacy or safety:

Major Interactions (Avoid)

• CYP3A4 inhibitors: Strong inhibitors such as ketoconazole may increase paclitaxel exposure and toxicity.
• CYP3A4 inducers: Strong inducers like rifampicin reduce paclitaticel ").

Moderate Interaction ( "). - "). - "}